Ana Oaknin

Ana Oaknin is a gynecologic oncology investigator leading a comprehensive clinical and translational program for uterine, cervical, and ovarian cancers in Spain. She co-led the GARNET trial that led to accelerated FDA approval of dostarlimab for MMR-deficient recurrent endometrial cancer. She participates in ENGOT (European Network of Gynecological Oncological Trial Groups) studies and has contributed to ESMO clinical practice guidelines for endometrial cancer. Her work shapes European evidence-based standards for gynecologic malignancy management.